Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Ceritinib,CER1001,2022,USA,MDV,350,62,45,55,27.5,60,85,5,15,30,40,15,55,25,15,5,20,35,45,18,7,4,9,6,22,58,42,Cisplatin + Pemetrexed,Carboplatin + Paclitaxel,Cisplatin + Vinorelbine,Carboplatin + Docetaxel,2,3,1,35,65,50,15,45,40,60,2
Ceritinib,CER1002,2023,Canada,Claim Database,420,68,48,52,28.1,55,80,7,18,28,38,16,52,27,16,5,22,33,45,20,8,5,10,7,20,60,40,Cisplatin + Gemcitabine,Carboplatin + Pemetrexed,Cisplatin + Etoposide,Carboplatin + Vinorelbine,1,4,2,40,70,55,10,50,40,65,3
Ceritinib,CER1003,2023,UK,MDV,280,65,42,58,26.9,65,78,6,16,32,38,14,58,24,13,5,19,36,45,17,6,3,8,5,25,55,45,Cisplatin + Docetaxel,Carboplatin + Gemcitabine,Cisplatin + Pemetrexed,Carboplatin + Etoposide,3,2,1,30,60,48,20,40,40,55,2.5
